Sign up USA
Proactive Investors - Run By Investors For Investors

XBiotech knocked hard by negative European cancer ruling

The Austin-based company was notified of a negative trend decision by the EMA
picture of cells
XBiotech said it was disappointed by the EMA indication

XBiotech Inc (NASDAQ:XBIT) crashed by 40% as the European Medicines Agency knocked back its colorectal cancer treatment antibody.

The Austin-based company was notified of a negative trend decision by the EMA, which makes it unlikely that a recommendation for use in humans would be received at the formal decision vote scheduled in May and additional steps to gain marketing approval are necessary.

John Simard, chief executive, said the company was disappointed.

“We believe that the data speak in a clear and resounding voice to clinical relevance of a new antibody therapy in advanced colorectal cancer.

"Findings from our Phase III study show that we have developed an important endpoint and methodology to evaluate anti-cancer therapy in advanced stage disease and that our monoclonal antibody represents a breakthrough treatment in patients with advanced colorectal cancer.”

An appeal is possible and Simard said as the decision was based on an oral meeting the company may go down this route 'at the appropriate time'.

XBiotech had been a strong performer ahead of the decision but its share price dropped US$6.80 to US$10.30 today.

PhilW.jpg


Register here to be notified of future XBIT Company articles
View full XBIT profile View Profile

XBiotech Timeline

Related Articles

Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
hepatitisC.jpg
March 27 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe
viagra.jpg
May 31 2017
Written responses from America’s Food & Drug Administration and the Medicines & Healthcare products Regulatory Agency (MHRA) here in Britain support its timeline, which sees marketing approval for the product in the second-quarter of 2019.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use